Abstract The activated leukocyte cell adhesion molecule (ALCAM) is overexpressed in many mammary tumors, but controversial results about its role and prognostic impact in breast cancer have been reported. Therefore, we evaluated the biologic effects of ALCAM expression in two breast cancer cell lines and a larger cohort of mammary carcinomas. By stable transfections, MCF7 cells with ALCAM overexpression and MDA-MB231 cells with reduced ALCAM levels were generated and analyzed in functional assays and cDNA microarrays. In addition, an immunohistochemical study on 347 patients with breast cancer with long-term follow-up and analysis of disseminated tumor cells (DTCs) was performed. In both cell lines, high ALCAM expression was associated with reduced cell motility. In addition, ALCAM silencing in MDA-MB231 cells resulted in lower invasive potential, whereas high ALCAM expression was associated with increased apoptosis in both cell lines. Among genes which were differentially expressed in clones with altered ALCAM expression, there was an overlap of 15 genes between both cell lines, among them cathepsin D, keratin 7, gelsolin, and ets2 whose deregulation was validated by western blot analysis. In MDA-MB231 cells, we observed a correlation with VEGF expression which was validated by enzymelinked immuno sorbent assay (ELISA). Our IHC results on primary breast carcinomas showed that ALCAM expression was associated with an estrogen receptor-positive phenotype. In addition, strong ALCAM immunostaining correlated with nodal involvement and the presence of tumor cells in bone marrow. By Kaplan-Meier analysis, strong ALCAM expression in ductal carcinomas correlated with shorter recurrence-free intervals (P = 0.048) and overall survival (OAS, P = 0.003). Our results indicate that the biologic role of ALCAM in breast cancer is complex, but overexpression might be relevant for outcome in ductal carcinomas.
Introduction
Adhesion molecules activate cancer-related biologic processes like survival, migration, extravasation, homing, and metastasis and thus play a crucial role in cancer progression. Many adhesion molecules are characteristically dysregulated in human cancer, and the development of therapeutic anti-adhesion strategies is ongoing. Therefore, better insights into the function of proteins involved in cell adhesion are necessary.
The activated leukocyte cell adhesion molecule (ALCAM) is a member of the immunoglobulin superfamily, consisting of five extracellular IgG domains (two V-type and three C 2 -type), a transmembrane anchoring region, and a short cytoplasmic tail. By homophilic (ALCAM-ALCAM) or heterophilic (ALCAM-CD6) ligand binding mediated by the distal domain (D1) and by lateral oligomerization mediated by the proximal C2-type domains (D3-D5), a clustering of ALCAM molecules and formation of an ALCAM network is achieved [1] . In normal tissues, ALCAM is expressed on activated lymphocytes, neuronal cells, hepatocytes, pancreatic cells, selected epithelia (i.e., in mammary ducts and acini), as well as in embryonic cells, i.e., bone marrow, endothelial, and yolk sac cells [1] [2] [3] . Moreover, it is localized at the lateral membranes of endothelial cells, where it facilitates transmigration of ALCAM-positive monocytes [4] .
Similar to other adhesion molecules, ALCAM binding can activate signaling pathways regulating various biologic functions. Thus, ALCAM expression has been implicated in apoptosis [5] , angiogenesis [6] , migration, and invasion [7] of various cell types. Concerning the role of ALCAM in human cancer, the results are partly controversial: In many tumors, ALCAM expression is associated with high invasive and metastatic potential and poor prognosis, i.e., in melanoma [8, 9] , colorectal cancer [10] , oral cancer [11] , pancreatic carcinoma [12] , and esophageal carcinoma [13] . In addition, metastatic clones of a mouse fibrosarcoma cell line are characterized by overexpression of ALCAM [14] . In contrast, tumor progression in prostate cancer is associated with ALCAM down-regulation [15] , and in an immunohistochemical study, loss of membrane staining was associated with an unfavorable prognosis in ovarian cancer [16] .
Investigations on breast cancer samples revealed contradictory results: ALCAM mRNA overexpression was associated with better prognosis in one study [17] , whereas ALCAM protein immunostaining (mainly cytoplasmic) was associated with poor survival in another cohort [18] . The lowest transcript levels were found in patients who developed bone metastasis [19] . The authors' analyses suggested that ALCAM might also have a predictive value in patients treated with conventional chemotherapy [20] .
In the light of these controversial results, we evaluated the role of ALCAM retrospectively in a larger cohort on a tissue microarray (TMA) including 347 patients with analysis of disseminated tumor cells (DTCs) in bone marrow and a median follow-up of 54.3 months, and by experimental studies using two breast cancer cell lines. Therefore, we generated stable clones with enhanced (MCF7) or reduced (MDA-MB231) ALCAM expression, which were compared to control cells in functional assays and by microarray analysis.
Materials and methods

Cell lines and generation of stable transfectants
MDA-MB231 and MCF7 breast cancer cell lines were cultivated in DMEM/F-12 medium (Gibco/Invitrogen, Darmstadt, Germany) supplemented with 10% FCS, antibiotics and, for MCF7 cells, 10 lg/ml insulin. The authenticity of our cells was validated by DSMZ GmbH (Braunschweig, Germany) before the beginning of the experiments. For generation of stable MCF7 cell clones with increased ALCAM expression, the OmicsLink ORF Expression Clone EX-H0002-M02 (GeneCopoeia, Germantown, Maryland) which contains the full-length ALCAM ORF was transfected into the cells, and stable transfectants were selected by addition of G418. For generation of MDA-MB231 cells with diminished ALCAM expression, the following sequences were synthesized and cloned into the pSilencer TM 3.1-H1 puro vector (Applied Biosystems/Ambion, Austin, TX, USA): 5 0 -GATCCAGTG TTCCCTGATAGACAATTCAA GAGATTGTCTATCAG GGAACACTGGTTTTTTGGAA A-3 0 (top strand) and 5 0 -A GCTTTTCCAAAAAACCAGTG TTCCCTGATAGACAA TCTCTTGAATTGTCTATCAG GGACACTG-3 0 (bottom strand). After transfection and selection of puromycin-resistant clones with reduced AL-CAM expression as shown in western blots, the sequences of the constructs were verified by direct sequencing. As controls, stable transfections with the appropriate control vectors EX-EGFP-MO2 (GeneCopoeia; for MCF7) or the pSilencer 3.1-H1 puro negative control vector containing a hairpin siRNA with limited homology to any known human sequences (Ambion; for MDA-MB231) were performed, and the resultant, antibiotic-resistant cells were used as negative controls for experiments of this study (MCF7-NC and MDA-shNC).
Immunocytochemistry
For immunocytochemistry, cells were grown on chamber slides for 2 days, fixed at -20°C in methanol for 10 min, then in acetone for 1 min. After rinsing in PBS, the sections were incubated with 10% horse serum (HS) containing 0.2% bovine serum albumin (BSA) for 15 min to block nonspecific binding sites, and incubated with the CD166/ALCAM specific antibody (1:300; Mab NCL-CD166, Novocastra Laboratories Ltd, Newcastle upon Tyne, UK) in PBS containing 1% HS and 0.2% BSA for 1 h at room temperature. After washing, bound antibodies were visualized using the Vectastain Elite ABC kit (Vector Laboratories, Burlingame, CA, USA) and counterstained with hematoxylin. Alternatively, the secondary antibody Alex488 (1:1000; Invitrogen-Molecular Probes, Karlsruhe, Germany) was applied for 60 min. Specimens were viewed and photographed either with a confocal microscope (Olympus Fluoview 1000, Olympus Deutschland GmbH Hamburg) or on a Zeiss Axioscope 40. Sections were coverslipped in ProLong Gold antifade reagent with DAPI (Invitrogen).
Functional assays
The invasive potential of the cells was tested with Matrigel TM Invasion Chambers (24-well plates; BD Biosciences, Heidelberg, Germany) according to the manufacturer's instructions with 25,000 cells per insert as described previously [21] . After a 48-h incubation, the cells which had passed the 8-lm pores of the membranes were counted under a microscope in seven identical square fields which together included most of the membrane area without the periphery. As controls, inserts without matrigel provided by the same manufacturer were used.
Motility was measured using a wound-healing assay. A band of cells, after attaining growth to confluence in sixwell plates, was removed using a sterile pipet tip. Gap closure was monitored, and the percentage of gap closure was estimated based on the photographs taken in regular intervals.
Apoptosis was shown by enrichment of nucleosomes in the cytoplasm of cells after addition of different concentrations of camptothecin (Cell Death Detection ELISA PLUS , Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer's instructions, and by M30 CytoDeath immunostaining. For the latter assay, cells were incubated with or without 0.4 lg/ml camptothecin for 16 h. After trypsinization, cytospins with 200,000 cells per slide were prepared and fixed in solution B (Epimet, Micromet, Munich, Germany) for 10 min, washed in TBST and blocked with Protein Block (Serum-free, Dako, Glostrup, Denmark) for 20 min, before the monoclonal anti-M30 antibody (Cyto DEATH, Fluorescein; 1:200, Roche, Mannheim, Germany) was applied at RT for 60 min. After washing with PBS, slides were again incubated with Protein Block (Serum-free, Dako) for 20 min. Subsequently, the monoclonal antibody A45-B/B3 labeled with Cy3 (1:300, Micromet) was applied at RT for 45 min followed by washing with PBS. Finally, slides were mounted with DAPI mounting medium. M30 staining was evaluated using a Zeiss Axioplan 2 fluorescence microscope and a 409 objective as number of apoptotic cells in at least 12 visual fields. All the functional assays were performed at least three times.
RNA isolation and microarray analysis from cell lines
Isolation of total RNA, cDNA synthesis, labeling, and hybridization to Affymetrix Human Genome GeneChip U133 Plus 2.0 were carried out as described [22] . To compare samples and experiments, the trimmed mean signal of each array was scaled to a target intensity of 200. Absolute and comparison analyses were performed with Affymetrix GCOS (version 1.4, Affymetrix) software using default parameters. For comparative analysis, the implemented Wilcoxon's Signed Rank Test was used. From Wilcoxon's Signed Rank test one-sided P-values were computed for each probe set (cut off P-value: 0.003). To assist in the identification of genes that were positively or negatively regulated in the experiment, we selected genes that were increased or decreased at least 1.74 fold (SLR C0.8) compared to the control.
Western blot analysis and ELISA tests General western blot conditions have been described [22] . For ALCAM detection and validation of differentially expressed genes, the following antibodies were used: ALCAM Mab NCL-CD166 (1:200; Novocastra); rabbit anti-Ets-2 antibody C20 (1:100; Santa Cruz Biotechnology, Heidelberg, Germany); mouse anti-NCAM-L1 (1:200, Santa Cruz); mouse anti-cathepsin D (1:500; Santa Cruz); mouse anti-CK7 clone OV-TL 12/30 (1:30000, Dako, Glostrup; Denmark); and mouse anti-gelsolin antibody (1:30000; DAKO). As secondary antibodies, peroxidaseconjugated anti-mouse-IgG (1:2000) or anti-rabbit-IgG (1:4000; all from Santa Cruz) were used, which were visualized by chemiluminescence reagents (Super Signal West Pico kit, Pierce, Rockfort, Ill.) with Hyperfilm ECL films (Amersham, Braunschweig, Germany). VEGF-165 in cell lysates and supernatants was quantified by commercially available ELISA (Siemens Healthcare Diagnostics, Tarrytown, USA) according to the manufacturer's instructions.
Patients and immunohistochemistry
In a retrospective study, immunohistochemistry was performed on a TMA which contained samples of 411 breast cancer patients who were treated at the Hamburg University Medical School between 1999 and 2006. Included were all those patients from this time span, from whom bone marrow had been taken and analyzed for the presence of DTCs as described [23] , based on availability of tumor material. The diagnosis including evaluation of histologic type and grading had been performed by pathologists on whole formalin-fixed paraffin-embedded tissue sections, and routine immunohistochemical determination of ER and PR status had been performed as described [24] . For TMA generation, 0.6-mm cores were taken from invasive parts of the tumors which had been selected by a pathologist. After exclusion of all the cases without residual tissue on TMA sections after IHC or without tumor cells in the 0.6-mm core, 347 cases became eligible for evaluation.
Patient data and tumor characteristics are described in Table 3 . The median age of the patients was 58.1 years (range 27.5-85.0 years), and the median follow-up time was 54.3 months (range 0.1-103.5 months). Patients received endocrine treatment and/or taxane-free chemotherapy according to national guidelines. No therapy like radiotherapy or neoadjuvant chemotherapy had been performed before operation. Before surgery, informed consent for the scientific use of tissue materials had been obtained from the patients in coordination with the local ethics committee according to the principles of the declaration of Helsinki. REMARK criteria were used through this report [25] .
Serial sections of 8 lm were cut from the TMA blocks using an adhesive-coated tape system (Tape-Transfer System, Instrumedics, Hackensack, NJ, USA), dewaxed with xylene and gradually hydrated. Heat-mediated antigen retrieval was achieved in hot 10 mM citrate buffer (pH 6.0) for 30 min, washed and incubated in 0.5% H 2 O 2 -methanol solution for 30 min. For immunohistochemistry, the Vectastain Elite ABC mouse Kit (Vector Laboratories, Burlingame, CA, USA) was used according to the manufacturer's instructions with the monoclonal antibody to CD166 (ALCAM) clone MOG/07 (1:400; Vector Lab.) incubated overnight at 4°C. As negative control, the primary antibody was omitted in parallel sections, resulting in negative ALCAM results (not shown). The ALCAM immunostaining was evaluated independently in a blinded fashion by two people using the immunoreactive score (IRS) as product of staining intensity (graded between 0 and 3) and percentage of positive cells (graded between 0 and 4; 1: 1-20%, 2: 21-50%; 3: 51-80%, 4: [80%) resulting in a score of 0-12. No differentiation between membraneous and cytoplasmic ALCAM staining was done. In case of differences between results, the samples were reviewed and a consensus was achieved.
Statistical analysis
Correlations between ALCAM protein expression and histological or clinical tumor characteristics were calculated by v 2 tests using the SPSS 15.0 software using groups described in Table 4 . For Kaplan-Meier analysis, overall survival (OAS) was computed from the date of diagnosis to the date of death due to distant metastasis. Kaplan-Meier survival curves were compared with the logrank test. Cox regression analysis was used to estimate Hazard ratios (HR) in uni-and multivariate analysis. Results of functional assays were compared by t-tests. All the tests were performed at a significance level of P = 0.05, and all P values are two-sided.
Results
ALCAM expression inhibits migration, but enhances invasion of breast cancer cells
In order to evaluate the impact of high ALCAM expression on the biologic properties of mammary cancer cells, experimental studies with two breast cancer cell lines were performed. In contrast to the highly invasive MDA-MB231 cells which are characterized by strong ALCAM expression as shown in western blots, ALCAM amounts in untransfected, weakly invasive MCF7 cells are relatively low. Therefore, MCF7 transfectants with ALCAM overexpression (clone # 1.3) as shown in western blots and two MDA-MB231 clones with strongly reduced ALCAM expression (# 14 and 9) were analyzed and compared with their respective controls. The localization of ALCAM proteins was demonstrated by immunocytochemistry. In MCF7-ALCAM cells, the adhesion molecule was localized in the cytoplasmic membranes in zones of cell-cell contacts, but not in membranes at the outer margins of cell clusters (Fig. 1a, b) . In untransfected MDA-MB231 cells, ALCAM expression was also mainly found in regions of cell-cell contacts. Only little cytoplasmic staining was observed in both cell lines (Fig. 1a, b) .
For all the functional tests, at least three experiments were performed. With respect to proliferation, the transfected clones did not differ from their parental cells (not shown). In wound-healing assays, the migration of MDA-MB231 cells was enhanced two-to threefold after ALCAM silencing by shRNA transfection (Fig. 1c) . Accordingly, motility of MCF7 cells was diminished by 20-30% after ALCAM overexpression (Fig. 1d) . In contrast, the invasive potential of MDA-MB231 cells as shown in matrigel invasion assays was strongly reduced in cells with ALCAM downregulation leading to a 80-90% reduction of invasive tumor cells, whereas there was no significant impact of ALCAM expression on cell invasion in MCF7 cells (Fig. 1e, f) . In control inserts without matrigel, no significant influence of ALCAM expression on the number of cells passing the pores was found (not shown).
ALCAM expression correlates with apoptosis in breast cancer cells
Apoptosis was monitored by enrichment of nucleosomes after addition of different concentrations of camptothecin and by M30 CytoDeath immunoreactivity. The M30 antibody recognizes a specific caspase cleavage site within cytokeratin 18 that is not detectable in normal epithelial cells. With both methods, the basal rate of apoptotic MCF7 cells was reproducibly higher in ALCAM transfectants compared to the control, although this difference did not reach statistical significance (Fig. 2a, c) . The difference in the number of nucleosomes diminished after addition of higher concentration of camtothecin (C0.4 lg/ml) (Fig. 2a) whereas the number of M30-positive cells in the presence of camptothecin was significantly higher in ALCAM transfectants (Fig. 2c) . In MDA-MB231, ALCAM downregulation was associated with a reduced percentage of apoptotic cells as shown by both methods. This difference persisted after addition of different concentrations of camptothecin (Fig. 2b, d ). Tables 1, 2) . Interestingly, overexpression of ALCAM results in up-regulation of additional adhesion molecules, namely NRCAM and CEACAM6 in MCF7 and L1-CAM and integrin ß5 in MDA-MB231 cells (Table 2 ). In addition, ALCAM expression correlates with higher levels of some components of the ECM, i.e., fibronectin and different collagen isoforms. In MDA-MB231 cells, proteins involved in angiogenesis were down-regulated by ALCAM silencing (i.e., VEGF-A), and in both cell lines, regulators of apoptosis were affected by ALCAM expression. A list of the most important deregulated genes is shown in Table 2 .
The regulation of some ALCAM target genes was validated on protein level. By western blot analysis, the downregulation of cytokeratin 7, cathepsin D, gelsolin, Ets2, and L1-CAM could be shown in MDA-MB231 cells, whereas only gelsolin and cytokeratin 7 up-regulation were validated in MCF7 cells (Fig. 3a) . In MDA-MB231 clones with reduced ALCAM expression, both intracellular and secreted VEGF protein levels were diminished as shown by ELISA experiments (Fig. 3b) . Similar to RNA results of this study, this validation could not be shown in MCF7 cells (Fig. 3c) .
ALCAM overexpression is associated with poor prognosis in breast cancer patients As prior results concerning the prognostic impact of ALCAM expression were partly controversial, we decided to analyze ALCAM protein expression in a larger, independent cohort. The clinical and histological characteristics of the cohort (n = 347) are shown in Table 3 . As the subcellular localization of the immunoreactivity was not always clearly definable, we did not differentiate between membraneous and cytoplasmic staining. In 74 cases (21%), no ALCAM staining was observed in tumor cells. Weak staining (IRS 1-3) in 136 tumor cases (39%), moderate staining (IRS 4-6) in 95 cases (27%), and strong staining (IRS 8-12) in 42 patients (12%), were observed (Fig. 3a-c) .
For statistical analysis, three groups of ALCAM-negative cases, tumors with weak/moderate immunoreactivity (IRS 1-6), and cases with strong staining (IRS 8-12), were generated, since tumors with weak and moderate expression behaved similarly (no significant differences). Using these groups, correlations with clinical and histological parameters were evaluated. There were highly significant positive associations with estrogen and progesterone receptor status (Table 4 ). In contrast, the correlation with histological grading showed a bimodal distribution, with an over-representation of negative or strong ALCAM staining in poorly differentiated tumors. No significant associations with tumor stage, age, or histological type were found (not shown).
In addition to lymph node involvement, the presence of DTCs in bone marrow is a potential risk factor for metastatic relapse in breast cancer [26] . In our cohort, ALCAM overexpression correlated significantly with nodal involvement (P = 0.006), and there was a tendency pointing to a higher rate of tumor cells in bone marrow in these patients (P = 0.084; Table 4 ).
By Kaplan-Meier analysis (median follow-up time 54.3 months), high ALCAM staining (IRS 8-12) was associated with shorter OAS compared to patients with low/moderate ALCAM scores (P = 0.021, Fig. 4 ). ALCAM-negative tumors had an intermediate position. In terms of recurrence-free survival (RFS), tumors with negative or weak/moderate results (ALCAM score 0-6) had a better prognosis compared to those with ALCAM overexpression, but this difference was statistically not significant (P = 0.279).
By stratification according to histological tumor type, we could show that the prognostic impact of ALCAM overexpression was more clear-cut in ductal carcinomas (OAS: P = 0.003; RFS: P = 0.048; Fig. 4 ), whereas in other types, no significant prognostic value was found (not shown). After further stratification according to endocrine or chemotherapy, no significant differences in RFS or OAS according to ALCAM levels in the respective subgroups were found (not shown).
For univariate Cox regression analysis, patients with negative and weak/moderate ALCAM staining were combined and compared to cases with ALCAM overexpression. Thus, a significant prognostic effect of overexpression on RFS (HR = 2.47, 95% CI: 1.17-5.22, P = 0.018) and OAS (HR = 4.32, 95% CI: 1.61-11.56, P = 0.004) was seen in ductal carcinomas. In the total cohort, the prognostic effect was not significant (RFS) or only marginally significant (OAS: HR = 2.34, 95% CI: 1.01-5.39, P = 0.047). By multivariate analysis including stage, nodal involvement, grading, ER status, and the presence of DTCs, the prognostic effect of ALCAM on RFS in ductal carcinomas curtly missed significance (P = 0.050; Table 5 ).
As in most studies, the median expression level was used as cut-off value, we performed the same analysis with two groups of similar size (IRS 0-2: n = 174; IRS 3-12: n = 173). By this approach, no significant correlations with clinical or histological parameters and disease outcome were found except an association of high ALCAM expression with nodal involvement (P = 0.006; not shown). 
Discussion
Although ALCAM expression has been shown in various tumor types, there is only limited knowledge about the biologic role of this adhesion molecule in cancer cells. In order to evaluate the effects of ALCAM expression in breast cancer cells in more detail, we performed functional assays with two cell lines. In both MDA-MB231 and MCF7 cells, high ALCAM levels were associated with a reduced motility in wound-healing assays, which corresponded to results obtained with other experimental systems: In endothelial-like yolk sac cells and human microvascular endothelial cells, ALCAM inhibited migration, but enhanced tube formation on matrigel [6] . Inhibition of ligand binding and of network formation by overexpression of a short secreted (s)ALCAM variant reversed this effect. Thus, escape of tumor cells from the tumor mass might be facilitated by loss of ALCAM-mediated cell-cell contacts. Interestingly, ALCAM enhanced the invasive potential of the hormone-receptor-negative MDA-MB231 cells. This corresponds to the aggressive nature of tumors with strong ALCAM immunostaining in our cohort of 347 patients, shown by lymph node involvement and shorter RFS and OAS. A role of ALCAM in cell invasion has been reported in melanoma cells where inhibition of ALCAM clustering by (s)ALCAM overexpression reduced invasion in a reconstituted skin model. Moreover, cells with (s)ALCAM expression were attenuated in metastasis frequency in a xenograft mouse model [7] . Similar to melanomas [27] , ALCAM might function as a cell surface sensor in breast cancer cells which regulates dynamic responses at high cell densities leading to enhanced invasion into the surrounding tissue. Apoptosis was positively influenced by ALCAM in both cell lines. This might result in an increased chemoresistance in these cells and corresponds well with our observations on clinical tumor tissues where high ALCAM levels are associated with better prognosis in chemotherapy-treated patients [20] .
In order to identify changes in gene expression which are induced by high ALCAM levels, cDNA microarrays were performed. Among the genes which are dysregulated in both MDA-MB231 and MCF7 cells, there was an overlap of 15 genes. Among those, cathepsin D might be involved in enhanced invasiveness of ALCAM-expressing MDA-MB231 cells. This aspartic protease is an independent predictor of early metastasis and shorter survival in mammary carcinomas [28, 29] . Most other genes which were deregulated in both cell lines have also been shown to be associated with tumorigenesis and tumor progression, e.g., PLAC1 [30] , amphiregulin (AREG) [31] , cytokeratin 7 [32] , RUNX2 [33] [34] [35] , STMN3 [36] , gelsolin [37] and fibronectin [38, 39] . Another target gene, the transcription factor Ets2, is frequently up-regulated in breast cancer [40, 41] . The enhanced apoptotic potential of cells with high ALCAM expression is in accordance with the increased expression of some pro-apoptotic genes in both cell lines (Table 2) . In contrast to others [5] , we did not observe an influence of ALCAM on BCL2 expression. Thus, the influence of ALCAM on apoptosis and chemoresistance should be further analyzed.
A high number of genes were deregulated in only one cell line. In MDA-MB231 cells, ALCAM silencing leads to reduced VEGF expression. A positive influence of ALCAM on angiogenesis has been shown in studies on endothelial cells [6] and in other experimental systems [42] . Moreover, comparison of gene expression profiles of ALCAM-positive, metastatic melanoma cell lines versus ALCAM-negative cell lines showed overexpression of VEGF [27] . The influence of ALCAM on cell invasion in MDA-MB231 cells also corresponds to its effect on expression of the adhesion molecule L1-CAM, which has been shown to enhance invasiveness of other cells [43, 44] , and is a negative prognostic parameter in mammary carcinomas [45] .
The signaling pathways which lead to changes in expression of these genes are still unclear, and further studies are required to elucidate these mechanisms. In other investigations, most of the biologic functions of ALCAM could be blocked by inhibition of ALCAM network formation which implies the presence and importance of membraneous ALCAM protein [7] . The question of whether similar pathways can also be activated by intracellular ALCAM which is observed in many tumors [18] should be further analysed.
In previous studies on the role of ALCAM in breast cancer, contradictory results indicating associations with good prognosis [17, 46] or poor outcome [18, 20] have been reported. This might be partially due to different technical or statistical approaches. In our immunohistochemical study, we differentiated between negative, weak/ moderate and strong ALCAM expression, and found the worst outcome in cases with strong ALCAM staining (Fig. 3) . If only two groups were analysed with the median ALCAM expression as cut-off value, no significant differences were found indicating that the results of ALCAM studies might be influenced strongly by the selected cut-off for statistical analysis.
By the approach above mentioned, the authors could show the previously reported correlation of ALCAM expression with an ER-/PR-positive phenotype which suggests an association with a more differentiated phenotype. On the other hand, strong ALCAM expression was associated with nodal involvement and shorter RFS and OAS, especially in ductal carcinomas. The presence of DTCs is a surrogate parameter of hematogenous tumor cell spread [47] . We observed an association of the presence of DTC with ALCAM expression which was not significant, probably due to the low incidence of DTC in patients with primary breast cancer applying restrictive evaluation criteria. A potential limitation of our immunohistochemical study is that the patients were not uniformly treated and that we have no untreated cohort. Therefore, we are not able to differentiate between prognostic and predictive effects of ALCAM expression in this cohort. In addition, the analysis of additional breast cancer cell lines would be interesting since the role of ALCAM is probably dependent on the tumor cell type.
In this study, the first functional analysis of the role of ALCAM in breast cancer cells is presented and correlated with data from human tumor tissues. In conclusion, our results indicate that the biologic role of ALCAM in breast cancer cells is complex and partially dependent on the tumor cell type. The effects of strong ALCAM overexpression on the biology of breast cancer cells might include decreased motility, enhanced invasive potential, and increased apoptosis. This might partly explain the contradictory results obtained with breast cancer samples where ALCAM was associated either with a positive or a negative prognosis [17, 18, 20, 46] . In a recent study, a human antibody phage library was screened for cancer-specific antibodies, resulting in an ALCAM-binding scFV antibody which inhibited invasiveness of MDA-MB231 cells and showed antitumor activity in an in vivo mouse colorectal carcinoma model [48] . In the light of the possible importance of ALCAM as target for cancer therapies, our results allow further insights into the biology of ALCAM in breast cancer. Other groups used for analysis: see Table 3 
